Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMIT Study: Amaryl M Initiation and Titration
NCT01144728Phase 4Completed
- Sponsor
- Sanofi
- Start
- May 2010
- Primary completion
- Dec 2010
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of glimepiride and liquid metformin (Aspargo Labs) in type 2 diabetes mellitus (T2DM), sponsored by Sanofi. Primary endpoints: Glycosylated Haemoglobin at 4 months, Patients With Glycosylated Haemoglobin < 7% at 4 months and 1 more. Started May 2010; status: completed.
02
Drugs
glimepirideliquid metformin (Aspargo Labs)
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01144728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01144728.